PVCT — Provectus Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $20.34m
- $22.57m
- $0.34m
Brief: Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10
RCS - VisiRose - VisiRose Introduces Therapy for Eye Infections
RCS - FINOS - FINOS Welcomes Seven Financial Leaders
Brief: Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting
Brief: Provectus Biopharmaceuticals Announces Presentation Of Cancer Immunotherapy PV-10 Poster For HNSCC At AACR 2024 Annual Meeting
Brief: Provectus Biopharmaceuticals Provides Updated Data On Cancer Immunotherapy Pv-10
Brief: Provectus Biopharmaceuticals Establishes Research Collaboration With University Of Tennessee College Of Veterinary Medicine
Brief: Provectus Biopharmaceuticals Announces Publication Of Activity Of Pharmaceutical-Grade Rose Bengal Sodium (Rbs) Against Colistin-Resistant Gram-Negative Bacteria
Brief: Provectus Biopharmaceuticals To Not Undertake Reverse Split Of Outstanding, Authorized Equities
Brief: Provectus Biopharma Names Aru Narendran To Scientific Advisory Board
Brief: Provectus Biopharmaceuticals Announces Oral Presentation Of Updated Study Data From Metastatic Neuroendocrine Cancer Phase 1 Trial Of Pv-10® At 2022 European Neuroendocrine Tumor Society (Enets) Annual Conference
Brief: Provectus Expands Global Patent Portfolio To India For Cancer Combination Therapy
Brief: Provectus Announces Presentation Of Preliminary Results From Phase 1 Trial Of PV-10
Brief: Provectus Biopharmaceuticals Appoints Heather Raines As CFO
Brief: U.S. FDA Grants PV-10 Orphan Drug Designation For Neuroblastoma
Brief: Provectus Announces Presentation Of Updated Results From Phase 1B Trial Of Pv-10 In Combination With Keytruda (Pembrolizumab)
Brief: Provectus Announces Resolution Of SEC Investigation
Brief: Provectus Biopharmaceuticals terminates Peter Culpepper as interim CEO and COO